Читать книгу Practical Cardiovascular Medicine - Elias B. Hanna - Страница 203

1 Statin, regardless of LDL. If needed, ezetimibe or PCSK-9 inhibitor may be added to achieve LDL <70 mg/dl.

2 HTN is controlled to <130/80 mmHg (ACC and SPRINT trial).⁵⁷

3 ACE-I is beneficial in CAD patients (HOPE and EUROPA trials),⁵⁸ more so in cases of EF <50%, HTN, diabetes, or CKD. In CAD patients with SBP 130–140 mmHg and normal EF, ACE-I did not show any benefit (PEACE trial).⁵⁹ In the early post-CABG setting (≤7 days) with normal EF and BP, ACE-I initiation did not improve outcomes and was associated with more adverse events in the first 3 months (IMAGINE trial).⁶⁰

4 Control of diabetes to a Hb A1c ≤7%.

5 Smoking cessation leads to a 50% reduction of the excessive risk of MI and stroke within 1 year (mostly within 2 months). At 3–5 years, the risk approaches that of never-smokers.